不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：树突状细胞-细胞因子诱导的杀伤细胞疗法用于慢性淋巴细胞白血病和腹膜癌受试者
英文原题：Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer.
查看英文原题
Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究旨在描述DC-CIK疗法分别在两名既往接受过治疗的慢性淋巴细胞白血病或腹膜癌患者中的安全性和疗效。参与者已接受针对其特定癌症的常规化疗，此外，受试者在1年内接受了1-2次DC-CIK治疗。受试者A在连续三天内接受了初始剂量的3次DC-CIK静脉输注，并在6个月后接受了重复剂量。受试者B在连续三天内接受了初始剂量的3次DC-CIK静脉输注，并在约1年后接受了进一步化疗。未报告治疗相关不良事件，且两名患者均从治疗中获得了有利结局，包括与典型5年生存率相比，治疗反应增强、化疗耐受性提高和生存期延长。
展开英文摘要原文
This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively. Participants had received conventional chemotherapy treatment for their specific cancers, and in addition, 1-2 treatments of DC-CIK therapy were administered to subjects over the course of 1 year. Subject A received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and a repeat dosage 6 months later.
Subject B received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and received further chemotherapy after approximately 1 year. No treatment-related adverse events were reported, and both patients experienced favorable outcomes from the treatment, including enhanced treatment response, increased chemotherapy tolerance, and prolonged survival in comparison to typical 5-year survival rates.
论文信息
- 作者
- Mehling B、Wu D、O'Gorman E、Sheridan D、Santora D、Mihályová R
- 第一作者单位
- BHI Therapeutic Sciences Inc., Hackensack, NJ, United States.United States
- 通讯作者单位
- Blue Horizon International, Bratislava, Slovakia.Slovakia
- 文献类型
- 病例报告
- 期刊
- Frontiers in medicine2023
- 原文标识
- PubMed 37877016 · DOI 10.3389/fmed.2023.1240330
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →